A new push from the U.S. Food and Drug Administration signals a major shift in how therapies may be tested before reaching patients. The agency is increasing support for alternatives to traditional animal testing, encouraging the use of advanced technologies such as artificial intelligence–driven modeling and organ-on-chip systems that simulate human biology. These tools can recreate complex organ functions on miniature chips and allow researchers to evaluate drug safety and effectiveness using human-relevant data. Advocates say these approaches could accelerate drug development, reduce costs, and produce results that better predict how treatments will perform in people. While animal testing will not disappear immediately, the FDA’s initiative marks a significant step toward modernizing biomedical research and expanding the role of emerging technologies in preclinical testing.